Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: A phase II, multicenter, randomized, dose-finding clinical trial

Clinical Infectious Diseases

Volumn 51, Issue 6, 2010, Pages 684-691

  Valecha, Neena ^a   Looareesuwan, Sornchai ^d   Martensson, Andreas ^e,f   Abdulla, Salim Mohammed ^g   Krudsood, Srivicha ^d   Tangpukdee, Noppadon ^d   Mohanty, Sanjib ^b   Mishra, Saroj K ^b   Tyagi, P K ^a   Sharma, S K ^a   Moehrle, Joerg ^h   Gautam, Anirudh ^c   Roy, Arjun ^c   Paliwal, Jyoti K ^c   Kothari, Monica ^c   Saha, Nilanjan ^c   Dash, Aditya P ^a   Björkman, Anders ^e,f  

^a NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^b ISPAT GENERAL HOSPITAL   (India)

^c Ranbaxy Research Laboratory   (India)

^d MAHIDOL UNIVERSITY   (Thailand)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g IFAKARA HEALTH INSTITUTE   (Tanzania)

^h Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARTEROLANE MALEATE; ASPARTATE AMINOTRANSFERASE; DISPIRO[ADAMANTANE 2,3' [1,2,4]TRIOXOLANE 5',4'' CYCLOHEXANEACETIC ACID 2 AMINO 2 METHYLPROPYLAMIDE]; HEMOGLOBIN; PARACETAMOL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TANZANIA; THAILAND; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIA; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PEROXIDES; PLASMODIUM FALCIPARUM; SPIRO COMPOUNDS; TANZANIA; THAILAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955951674     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655831     Document Type: Article

References (21)

1. World Health Organization. World malaria report 2008. Document WHO/HTM/GMP/2008.1. Geneva: World Health Organization, 2008. http://www.who.int/malaria/wmr2008/malaria2008.pdf. Accessed 14 May 2009.
2. Bloland PB. Drug resistance in malaria. Document WHO/CDS/CSR/ DRS/2001.4. Geneva: World Health Organization, 2001. http://www.who.int/csr/resources/ publications/drugresist/malaria.pdf. Accessed 14 May 2009.
3. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007; 4:e309.
4. Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002; 415:686-693
5. Shanks GD. Treatment of falciparum malaria in the age of drug resistance. J Postgrad Med 2006; 52:277-280
6. Vennerstrom JL, Arbe-Barnes S, Brun R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004; 430:900-904
7. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 2002; 46:778-782
8. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated P. falciparum malaria. Document WHO/HTM/RBM/2003.50. Geneva: World Health Organization, 2003.
9. Felger I, Beck HP. Genotyping of Plasmodium falciparum: PCR-RFLP analysis. Methods Mol Med 2002; 72:117-129
10. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7:549-558
11. Von SL, Jaffar S, Greenwood B. Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 1997; 56:494-497
12. Giao PT, Binh TQ, Kager PA, et al. Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy? Am J Trop Med Hyg 2001; 65:690-695
13. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996; 60:301-315
14. McIntosh HM, Olliaro P. Artemisinin derivatives for treating severe malaria. Cochrane Database Syst Rev 2000; 2:CD000527.
15. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-1658
16. Menard D, Matsika-Claquin MD, Djalle D, et al. Association of failures of seven-day courses of artesunate in a non-immune population in Bangui, Central African Republic with decreased sensitivity of Plasmodium falciparum. Am J Trop Med Hyg 2005; 73:616-621
17. Enevold A, Nkya WM, Theisen M, et al. Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J 2007; 6:153.
18. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization, 2010. http://www.who.int/ malaria/publications/atoz/9789241547925/en/index.html. Accessed 1 August 2010.
19. Davis TME, Hung TY, Sim IK, et al. Piperaquine: a resurgent antimalarial drug. Drugs 2005; 65:75-87.
20. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320:330-334
21. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-467